Impact of ILM Peeling in RRD/ I-Peel (I-Peel)
Primary Purpose
Retinal Detachment
Status
Enrolling by invitation
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
ILM (inner limiting membrane) peeling
Sponsored by
About this trial
This is an interventional treatment trial for Retinal Detachment focused on measuring retinal detachment, ILM-peeling
Eligibility Criteria
Inclusion Criteria:
- primary rhegmatogenous retinal detachment
- of legal age (18 years or older)
- in case of bilateral retinal detachment, only the first-affected eye will be included
Exclusion Criteria:
- pre-existing functional and morphological changes to the macula, hindering visual recovery (amblyopia, trauma, macular degeneration)
- advanced retinal detachment with PVR stage C2 or more
- eyes pre-operated within six months prior to the development of RD
- state after any vitreoretinal surgery
- state after complicated cataract surgery, including aphakia and anterior chamber lens implantation
- patients with increased risk profiles
- myopia magna (≥7 diopters)
- advanced diabetic retinopathy
- any chronic ocular or systemic inflammatory disease
- any other proliferative systemic disease or condition associated with impaired wound healing
Sites / Locations
- Berner Augenklinik
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
ILM (inner limiting membrane) peeling
No Peeling
Arm Description
ILM peeling adding to standard vitreous surgery in patients suffering from retinal detachment
standard vitreous surgery without ILM peeling in patients suffering from retinal detachment
Outcomes
Primary Outcome Measures
Number of patients developing secondary epiretinal membrane formation
Clinically significant secondary epiretinal membrane formation requiring revision surgery
Secondary Outcome Measures
Rate of re-detachments in patients
Revision surgery due to re-detachment independently of secondary epiretinal membrane formation
Best-corrected visual acuity
Change in best-corrected visual acuity
Complication rates
Intra- and postoperative complication rates including PVR
Surgical times
How long does the surgery take
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04767555
Brief Title
Impact of ILM Peeling in RRD/ I-Peel
Acronym
I-Peel
Official Title
Impact of ILM Peeling on Functional and Anatomic Outcomes of Vitrectomy for Primary Rhegmatogenous Retinal Detachment - the I-Peel Study
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
February 23, 2022 (Actual)
Primary Completion Date
April 2025 (Anticipated)
Study Completion Date
June 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Berner Augenklinik
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Retinal detachment is associated with a substantial risk of re-detachment in 10-20% and to the formation of secondary epiretinal membranes in up to 15%. Relevant postoperative vision loss is encountered in many instances, primarily in consequence of macular involvement, but also secondarily due to postoperative complications, namely the formation of an epiretinal membrane and proliferative vitreoretinopathy. These mechanical reasons of influence can potentially be prevented by ILM peeling during reattachment surgery. This, however, is not a generally accepted standard of care during primary routine vitrectomy.
Two groups suffering from primary retinal detachment will be compared: the first group will receive standard re-attachment vitrectomy surgery, whereas the second group will receive an identical vitrectomy surgery, but with additional ILM peeling. In this study, the investigators wish to assess the influence of ILM peeling on visual outcomes and postoperative complications over 12 months.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Retinal Detachment
Keywords
retinal detachment, ILM-peeling
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
250 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
ILM (inner limiting membrane) peeling
Arm Type
Experimental
Arm Description
ILM peeling adding to standard vitreous surgery in patients suffering from retinal detachment
Arm Title
No Peeling
Arm Type
No Intervention
Arm Description
standard vitreous surgery without ILM peeling in patients suffering from retinal detachment
Intervention Type
Procedure
Intervention Name(s)
ILM (inner limiting membrane) peeling
Intervention Description
The standard technique for the removal of the inner limiting membrane is a dye-assisted ILM peeling established since 20 years as the standard of care to treat vision loss due to epiretinal membranes or macular holes in eyes with an otherwise stable retina, but not during retinal detachment surgery. Other dyes may show a stronger staining effect but since there is evidence of a potential toxicity of ICG the investigators use the well-tolerated and for this purpose approved trypan blue dye Membrane Blue ® (Dorc). This intervention will be performed in addition to standard vitreoretinal re-attachment surgery.
Primary Outcome Measure Information:
Title
Number of patients developing secondary epiretinal membrane formation
Description
Clinically significant secondary epiretinal membrane formation requiring revision surgery
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Rate of re-detachments in patients
Description
Revision surgery due to re-detachment independently of secondary epiretinal membrane formation
Time Frame
12 months
Title
Best-corrected visual acuity
Description
Change in best-corrected visual acuity
Time Frame
12 months
Title
Complication rates
Description
Intra- and postoperative complication rates including PVR
Time Frame
12 months
Title
Surgical times
Description
How long does the surgery take
Time Frame
minutes (0-300)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
110 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
primary rhegmatogenous retinal detachment
of legal age (18 years or older)
in case of bilateral retinal detachment, only the first-affected eye will be included
Exclusion Criteria:
pre-existing functional and morphological changes to the macula, hindering visual recovery (amblyopia, trauma, macular degeneration)
advanced retinal detachment with PVR stage C2 or more
eyes pre-operated within six months prior to the development of RD
state after any vitreoretinal surgery
state after complicated cataract surgery, including aphakia and anterior chamber lens implantation
patients with increased risk profiles
myopia magna (≥7 diopters)
advanced diabetic retinopathy
any chronic ocular or systemic inflammatory disease
any other proliferative systemic disease or condition associated with impaired wound healing
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Justus G Garweg, Prof. Dr.
Organizational Affiliation
Berner Augenklinik
Official's Role
Principal Investigator
Facility Information:
Facility Name
Berner Augenklinik
City
Bern
ZIP/Postal Code
3007
Country
Switzerland
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
19107502
Citation
Aras C, Arici C, Akar S, Muftuoglu G, Yolar M, Arvas S, Baserer T, Koyluoglu N. Peeling of internal limiting membrane during vitrectomy for complicated retinal detachment prevents epimacular membrane formation. Graefes Arch Clin Exp Ophthalmol. 2009 May;247(5):619-23. doi: 10.1007/s00417-008-1025-y. Epub 2008 Dec 24.
Results Reference
background
PubMed Identifier
18055572
Citation
Garweg JG, Bergstein D, Windisch B, Koerner F, Halberstadt M. Recovery of visual field and acuity after removal of epiretinal and inner limiting membranes. Br J Ophthalmol. 2008 Feb;92(2):220-4. doi: 10.1136/bjo.2007.131862. Epub 2007 Nov 30.
Results Reference
background
PubMed Identifier
29394235
Citation
Garweg JG, Deiss M, Pfister IB, Gerhardt C. IMPACT OF INNER LIMITING MEMBRANE PEELING ON VISUAL RECOVERY AFTER VITRECTOMY FOR PRIMARY RHEGMATOGENOUS RETINAL DETACHMENT INVOLVING THE FOVEA. Retina. 2019 May;39(5):853-859. doi: 10.1097/IAE.0000000000002046.
Results Reference
background
PubMed Identifier
25204530
Citation
Hohn F, Kretz FT, Pavlidis M. [Primary vitrectomy with peeling of the internal limiting membrane under decaline: a promising surgical maneuver for treatment of total and subtotal retinal detachment]. Ophthalmologe. 2014 Sep;111(9):882-6. doi: 10.1007/s00347-014-3158-1. German.
Results Reference
background
PubMed Identifier
15834606
Citation
Kodjikian L, Richter T, Halberstadt M, Beby F, Flueckiger F, Boehnke M, Garweg JG. Toxic effects of indocyanine green, infracyanine green, and trypan blue on the human retinal pigmented epithelium. Graefes Arch Clin Exp Ophthalmol. 2005 Sep;243(9):917-25. doi: 10.1007/s00417-004-1121-6. Epub 2005 Apr 15.
Results Reference
background
PubMed Identifier
9413690
Citation
Koerner F, Garweg J. Advances in the management of vitreomacular traction syndrome and macular hole. Dev Ophthalmol. 1997;29:15-29. doi: 10.1159/000060723. No abstract available.
Results Reference
background
PubMed Identifier
21878849
Citation
Odrobina D, Bednarski M, Cisiecki S, Michalewska Z, Kuhn F, Nawrocki J. Internal limiting membrane peeling as prophylaxis of macular pucker formation in eyes undergoing retinectomy for severe proliferative vitreoretinopathy. Retina. 2012 Feb;32(2):226-31. doi: 10.1097/IAE.0b013e31821a12e9.
Results Reference
background
Learn more about this trial
Impact of ILM Peeling in RRD/ I-Peel
We'll reach out to this number within 24 hrs